(Q48894607)

16 February 2018

title

Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system (English)

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

2 November 2022

author name string

M. Jibson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699614

2 November 2022

K. F. Faull

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699614

2 November 2022

J. G. Csernansky

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1699614

2 November 2022

language of work or name

English

0 references

publication date

1 October 1990

1 reference

16 February 2018

full work available at URL

https://api.elsevier.com/content/article/PII:000632239090397K?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

https://api.elsevier.com/content/article/PII:000632239090397K?httpAccept=text/plain

2 November 2022

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

2 November 2022

published in

Biological Psychiatry

1 reference

16 February 2018

volume

28

1 reference

16 February 2018

issue

7

1 reference

16 February 2018

page(s)

595-602

1 reference

16 February 2018

Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF.

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Indoleamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline

2 November 2022

2

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

CSF monoamine metabolites in depression and schizophrenia

2 November 2022

3

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Clinical measurements of central dopamine and 5-hydroxytryptamine metabolism: reliability and interpretation of cerebrospinal fluid acid monoamine metabolite measures.

2 November 2022

4

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Plasma homovanillic acid concentration and the severity of schizophrenic illness

2 November 2022

6

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Selected ion monitoring assay for biogenic amine metabolites and probenecid in human lumbar cerebrospinal fluid

2 November 2022

8

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Monoamine metabolite concentrations in the cerebrospinal fluid of normal and narcoleptic dogs

2 November 2022

9

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

A selective ion monitoring assay for probenecid

2 November 2022

10

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Clinical application of the probenecid test for measurement of monoamine turnover in the CNS

2 November 2022

12

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Active transport of 5-hydroxyindoleacetic acid by the rabbit choroid plexus in vitro. Blockade by probenecid and metabolic inhibitors.

2 November 2022

13

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls

2 November 2022

15

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Computerized axial tomography scans and subtypes of schizophrenia. A review of the literature.

2 November 2022

16

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Effect of probenecid on free 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and its sulphate in human cerebrospinal fluid

2 November 2022

17

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Cerebrospinal fluid HVA, central brain atrophy, and clinical state in schizophrenia

2 November 2022

18

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Monoamine neurotransmitter interactions and the prediction of antidepressant response

2 November 2022

19

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

CSF and urinary biogenic amines and metabolites in depression and mania. A controlled, univariate analysis

2 November 2022

21

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Correlates of lateral ventricular size in chronic schizophrenia, II: biological measures

2 November 2022

23

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers

2 November 2022

25

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

CSF amine metabolites and depression

2 November 2022

26

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Effects of psychotropic drugs on neurotransmitters in man

2 November 2022

28

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio

2 November 2022

29

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Pathological gambling. A psychobiological study

2 November 2022

30

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?

2 November 2022

31

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients

2 November 2022

32

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Plasma levels of chlorimipramine and its demethyl metabolite during treatment of depression

2 November 2022

34

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy

2 November 2022

35

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients

2 November 2022

37

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

Clearance of 3-methoxy-4-hydroxyphenylglycol from the cerebrospinal fluid

2 November 2022

38

1 reference

https://api.crossref.org/works/10.1016/0006-3223(90)90397-K

2 November 2022

Identifiers

1 reference

16 February 2018

1 reference

16 February 2018